Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Apr 5, 2018
Open Peer Review Period: Apr 7, 2018 - Jun 2, 2018
Date Accepted: Aug 26, 2018
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Digital Technology in Somatic and Gene Therapy Trials of Pediatric Patients With Ocular Diseases: Protocol for a Scoping Review

Meinert E, Alturkistani A, Osama T, Halioua-Haubold CL, Car J, Majeed A, Wells G, MacLaren RE, Brindley D

Digital Technology in Somatic and Gene Therapy Trials of Pediatric Patients With Ocular Diseases: Protocol for a Scoping Review

JMIR Res Protoc 2019;8(2):e10705

DOI: 10.2196/10705

PMID: 30730295

PMCID: 6383115

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Digital Technology in Somatic and Gene Therapy Trials of Pediatric Patients With Ocular Diseases: Protocol for a Scoping Review

  • Edward Meinert; 
  • Abrar Alturkistani; 
  • Tasnime Osama; 
  • Celine-Lea Halioua-Haubold; 
  • Josip Car; 
  • Azeem Majeed; 
  • Glenn Wells; 
  • Robert E MacLaren; 
  • David Brindley

Background:

Pharmacogenomics suggests that diseases with similar symptomatic presentations often have varying genetic causes, affecting an individual patient’s response to a specific therapeutic strategy. Gene therapies and somatic cell therapies offer unique therapeutic pathways for ocular diseases and often depend on increased understanding of the genotype-phenotype relationship in disease presentation and progression. While demand for personalized medicine is increasing and the required molecular tools are available, its adoption within pediatric ophthalmology remains to be maximized in the postgenomic era.

Objective:

The objective of our study was to address the individual hurdles encountered in the field of genomic-related clinical trials and facilitate the uptake of personalized medicine, we propose to conduct a review that will examine and identify the digital technologies used to facilitate data analysis in somatic and gene therapy trials in pediatric patients with ocular diseases.

Methods:

This paper aims to present an outline for Healthcare Information Technology and Information and Communication Technology resources used in somatic and gene therapy clinical trials in children with ocular diseases. This review will enable authors to identify challenges and provide recommendations, facilitating the uptake of genetic and somatic therapies as therapeutic tools in pediatric ophthalmology. The review will also determine whether conducting a systematic review will be beneficial.

Results:

Database searches will be initiated in September 2018. We expect to complete the review in December 2019.

Conclusions:

Based on review findings, the authors will summarize methods used for facilitating IT integration in personalized medicine. Additionally, it will identify further research gaps and determine whether conducting further reviews will be beneficial.

International Registered Report:

PRR1-10.2196/10705


 Citation

Please cite as:

Meinert E, Alturkistani A, Osama T, Halioua-Haubold CL, Car J, Majeed A, Wells G, MacLaren RE, Brindley D

Digital Technology in Somatic and Gene Therapy Trials of Pediatric Patients With Ocular Diseases: Protocol for a Scoping Review

JMIR Res Protoc 2019;8(2):e10705

DOI: 10.2196/10705

PMID: 30730295

PMCID: 6383115

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.